Prevalence of Multidrug-Resistant Tuberculosis in HIV/Tuberculosis Co-Infected Patients

Lee, Chan Mi; Lee, Eun-Young; Bang, Ji Hwan; Park, Sang-Won; Park, Wan Beom; Oh, Myoung‐don; Kim, Nam Joong

doi:10.3947/ic.2021.0085

Cited by 5 publications

(2 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The objective of this study was to analyse the clinical characteristics of HIV+ and HIVtuberculosis patients followed and treated at the Oyem Regional Hospital (CHRO). Contrary to the results obtained in Brazil 27.7%, Cameroon26.06%, Togo 23.7% and even Korea 15.9% [7,8,9,10,11], the present study indicated ; which is rather close to that found in Morocco 39.3%. This diversity of results could be due, on the one hand, to the difference in the timing, season and year of the studies, the sampling of participants, socio-demographic factors, and environmental conditions in these study areas.…”

Section: Discussioncontrasting

confidence: 88%

Clinical Characteristics and Treatment Outcomes of HIV+ and HIV- Tuberculosis Patients Followed and Treated at the Regional Hospital of Oyem, Northern Gabon: A Two-Year Retrospective Study

Obiang

Ndong²,

Moundounga³

et al. 2022

MRJI

View full text Add to dashboard Cite

Background: The objective of this study was to analyse the clinical characteristics of HIV+ and HIV- tuberculosis patients followed and treated at the Oyem Regional Hospital Centre (ORHC). Materials and Methods: During this study conducted between January 2019 and December 2021, data collection was based on the exploitation of medical records and registers of results from the medical analysis laboratory of the regional hospital of Oyem, in which there were personal data (gender and age) of the patients, the status of HIV infection, clinical characteristics (pulmonary or extra pulmonary TB), and finally, the therapeutic outcomes of the patients after anti-tuberculosis and antiretroviral treatment. Binomial test following the Normal distribution was used to find an association between the percentages of extrapulmonary TB and TB+/HIV+ co-infection. Results: In this study, 128 confirmed TB cases were selected. While 54 (42.19%) were co-infected with TB+/HIV+, 74 patients (57.81%) were monoinfected with TB+/HIV+. Among all these patients, 93 (72.66%) were reported to have extra pulmonary TB and 35 (27.34%) had pulmonary TB. A normal binomial test showed that TB+/HIV+ co-infection was significantly associated with extrapulmonary TB (p=0.04). Patients were put on anti-tuberculosis treatment according to the manufacturers' indications. Despite a total of 15 deaths (8.93%) in both mono- and co-infected patients, there was a favourable outcome, with 35 patients (27.34%) declared cured. With 8 deaths, mortality was higher in the co-infected than in the non-HIV infected TB patients who recorded 7 deaths. Conclusion: By indicating a relatively high prevalence of HIV infection in TB patients, this study showed that TB+/HIV+ co-infection was associated with extra pulmonary TB, the severe form of the disease, and increased mortality in patients, hence the need to strengthen joint activities to control this co-infection.

show abstract

Section: Discussioncontrasting

confidence: 88%

Clinical Characteristics and Treatment Outcomes of HIV+ and HIV- Tuberculosis Patients Followed and Treated at the Regional Hospital of Oyem, Northern Gabon: A Two-Year Retrospective Study

Obiang

Ndong²,

Moundounga³

et al. 2022

MRJI

View full text Add to dashboard Cite

show abstract

“…Among these 15 studies, all MDRTB and HIV-positive individuals have multidrug-resistant. 10 studies [18] , [19] , [20] , [21] , [22] , [24] , [25] , [26] , [27] , [29] showed resistance to first line anti-TB drug Isoniazid and 8 studies [ [18] , [19] , [20] , 22 , 24 , 25 , 27 , 29 ] showed resistance to another first line anti-TB drug Rifampin. Along with this, 3 studies [ 18 , 22 , 26 ] showed streptomycin resistance; one study [ 17 ] showed isoniazid streptomycin resistance, two studies [ 18 , 22 ] ethambutol resistance; one study [ 21 ] showed rifampin and ethambutol resistance, four studies [ 23 , 28 , 30 , 31 ] showed isoniazid and Rifampin resistance, one study [ 24 ] showed Pyrazinamide resistance and one study [ 28 ] showed Streptomycin and ethambutol Resistance.…”

Section: Resultsmentioning

confidence: 99%